Overview of gemcitabine triplets in metastatic bladder cancer

Critical Reviews in Oncology/Hematology

Volumn 45, Issue 2, 2003, Pages 191-197

  De Wit, Ronald ^a   Bellmunt, Joaquim ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bladder cancer; Chemotherapy; Cisplatin; Gemcitabine; Paclitaxel; Urothelial cell cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; PLATINUM;

BLADDER CANCER; CANCER SURVIVAL; CHEMOTHERAPY; DRUG EFFICACY; HUMAN; METASTASIS; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 0037320086     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00079-3     Document Type: Review

References (50)

1. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer. 60:1987;574-585.
2. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133:1985;403-407.
3. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer. 64:1989;2448-2458.
4. Tannock I., Gospodarowicz M., Connolly J., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital Experience. J. Urol. 142:1989;289-292.
5. Igawa M., Ohkuchi T., Ueki T., et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J. Urol. 144:1990;662-665.
6. Boutan-Laroze A., Mahjoubi M., Droz J.P., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. Eur. J. Cancer. 27:1991;1690-1694.
7. Loehrer P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10:1992;1066-1073.
8. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8:1990;1050-1055.
9. Geller N.L., Sternberg C.N., Penenberg D., et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer. 67:1991;1525-1531.
10. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17:1999;3173-3181.
11. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase IIII intergroup study of cisplatin alone or in cobination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 15:1997;2564-2569.
12. Connor J.P., Olsson C.A., Benson M.C., et al. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of the urinary bladder: cause for concern. Urology. 34:1989;353-356.
13. Wit de R., Tesselaar M., Kok T.C., et al. Randomized phase II trial of carboplatin and iproplatin in advanced urothelial cancer. Eur. J. Cancer. 27:1991;1383-1385.
14. Bellmunt J., Albanell J., Gallego O., et al. Carboplatin, Methotrexate, and Vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer. 70:1992;1974-1979.
15. Boccardo F., Pace M., Guarneri D., et al. Carboplatin, methotrexate and vinblastine in the treatment of patients with advanced urothelial cancer. Cancer. 73:1994;1932-1936.
16. Bellmunt J., Ribas A., Eres N., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 80:1997;1966-1972.
17. Roth B.J., Dreicer R., Einhorn L.H., et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (E1892). J. Clin. Oncol. 12:1994;2264-2270.
18. Papamichael D., Gallagher C.J., Oliver R.T.D., et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br. J. Cancer. 75:1997;606-607.
19. Broome C.M., Hussain M., Gutheil J., et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;351. (abstr. 1381).
20. Wit de R., Kruit W.H.J., Stoter G., et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br. J. Cancer. 78:1998;1342-1345.
21. McCaffrey J.A., Hilton S., Mazumdar M., et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 15:1997;1853-1857.
22. Pollera C.F., Ceribelli A., Crecco M., et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann. Oncol. 5:1994;182-184.
23. Stadler W.M., Kuzel T., Roth B., et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. 15:1997;3394-3398.
24. Moore M.J., Tannock I.F., Ernst D.S., et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J. Clin. Oncol. 15:1997;3441-3445.
25. Lorusso V., Pollera C.F., Antimi M., et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum: Italian Cooperative Group on Bladder Cancer. Eur. J. Cancer. 34:1998;1208-1212.
26. Gebbia V., Testa A., Borsellino N., et al. Single agent 2′,2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin. Ter. 150:1999;11-15.
27. Albers P., Siener R., Perabo F.G., et al. Gemcitabine monotherapy as 2nd-line treatment in cisplatin refractory transitional cell carcinoma. Proc. Am. Soc. Clin. Oncol. 19:2000;346a. (abstr. 1360).
28. Murphy B.A., Johnson D.R., Smith J., et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc. Am. Soc. Clin. Oncol. 15:1996;245. (abstr. 617).
29. Burch P.A., Richardson R.L., Cha S.S., et al. Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma. Proc. Am. Soc. Clin. Oncol. 18:1999;329. (abstr. 1266).
30. Dreicer R., Manola J., Roth B., et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group (ECOG) study. J. Clin. Oncol. 18:2000;1058-1061.
31. Dimopoulos M.A., Bakoyannis C., Georgoulias V., et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann. Oncol. 10:1999;1385-1388.
32. Sengeløv L., Kamby C., Lund B., et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J. Clin. Oncol. 16:1998;3392-3397.
33. Garcia del Muro, Marcuello E., Guma R., et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br. J. Cancer. 86:2002;326-330.
34. Pycha A., Grbovic M., Posch B., et al. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urol. 53:1999;510-515.
35. Droz JP, Mottel N, Prapotrich D, et al. Phase II study of taxol (Paclitaxel) and carboplatin in patients with advanced transitional-cell carcinoma of the urothelium: preliminary results, Proc Am Soc Clin Oncol 1998;17: 316a, (abstr. 1219).
36. Bauer J., Stalder M., Roth A., et al. Phase II trial of paclitaxel (P) plus carboplatin (C) in advanced urothelial tract cancer (UTC). Proc. Am. Soc. Clin. Oncol. 17:1998;326a. (abstr. 1255).
37. Vaughn D.J., Malkowicz S.B., Zoltick B., et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 16:1998;255-260.
38. Redman B.G., Smith D.C., Flaherty L., et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J. Clin. Oncol. 16:1998;1844-1848.
39. Small E.J., Lew D., Redman B.G., et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J. Clin. Oncol. 18:2000;2537-2544.
40. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22:(Suppl. 11):1995;72-79.
41. Van Moorsel C.J., Veerman G., Vermorken J.B., et al. Mechanisms of synergism between gemcitabine and cisplatin. Source Adv. Exper. Med. Biol. 431:1998;581-585.
42. Von der Maase H., Andersen L., Crino L., et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann. Oncol. 10:1999;1461-1465.
43. Moore M.J., Winquist E.W., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17:1999;286-2881.
44. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18:2000;1921-1927.
45. Von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 17:2000;3068-3077.
46. Lippert C.M., Koser M.F. Gemcitabine and cisplatinum in a 21 day schedule in the first-line treatment of locally advanced or metastatic transitional cell carcinoma; preliminary results of a phase II study. Proc. Am. Soc. Clin. Oncol. 20:2001;196. (abstr. 783).
47. Bellmunt J., Guillem V., Paz-Ares L., et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J. Clin. Oncol. 18:2000;3247-3255.
48. Hussain M., Vaishampayan U., Du W., et al. Combination carboplatin, paclitaxel and gemcitabine. Is an active teatment for advanced urothelial carcinoma. J. Clin. Oncol. 19:2001;2527-2533.
49. Bellmunt J, Albanell J, Paz-Ares L, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine, Cancer 2002 (in press).
50. Bellmunt J., Wit de R., Albanell J., et al. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Eur. J. Cancer. 37:2001;2212-2215.